GSA Capital Partners LLP decreased its holdings in Quest Diagnostics Inc (NYSE:DGX) by 68.2% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,869 shares of the medical research company’s stock after selling 14,725 shares during the period. GSA Capital Partners LLP’s holdings in Quest Diagnostics were worth $755,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. Wells Fargo & Company MN boosted its stake in shares of Quest Diagnostics by 0.5% in the 1st quarter. Wells Fargo & Company MN now owns 1,571,810 shares of the medical research company’s stock valued at $157,652,000 after purchasing an additional 7,141 shares in the last quarter. Commerzbank Aktiengesellschaft FI boosted its stake in shares of Quest Diagnostics by 38.5% in the 1st quarter. Commerzbank Aktiengesellschaft FI now owns 2,904 shares of the medical research company’s stock valued at $291,000 after purchasing an additional 808 shares in the last quarter. Mackay Shields LLC acquired a new stake in shares of Quest Diagnostics in the 1st quarter valued at $2,301,000. Boston Partners acquired a new stake in shares of Quest Diagnostics in the 1st quarter valued at $5,578,000. Finally, Massachusetts Financial Services Co. MA boosted its stake in shares of Quest Diagnostics by 1.4% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 612,316 shares of the medical research company’s stock valued at $61,416,000 after purchasing an additional 8,736 shares in the last quarter. 86.27% of the stock is owned by institutional investors.

DGX has been the topic of several recent analyst reports. Mizuho restated a “buy” rating on shares of Quest Diagnostics in a research note on Friday, May 25th. Zacks Investment Research upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating and set a $115.00 target price on the stock in a research note on Tuesday, May 22nd. MED downgraded shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Wednesday, June 27th. Deutsche Bank downgraded shares of Quest Diagnostics from a “buy” rating to a “hold” rating and set a $108.00 target price on the stock. in a research note on Wednesday, June 27th. Finally, Barclays restated a “hold” rating and issued a $120.00 target price on shares of Quest Diagnostics in a research note on Monday, May 28th. Twelve investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $110.00.

In other Quest Diagnostics news, SVP Everett Cunningham sold 40,328 shares of the business’s stock in a transaction dated Tuesday, July 10th. The stock was sold at an average price of $112.00, for a total transaction of $4,516,736.00. Following the completion of the sale, the senior vice president now directly owns 78,589 shares of the company’s stock, valued at approximately $8,801,968. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.79% of the company’s stock.

Quest Diagnostics stock opened at $108.36 on Wednesday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.12 and a quick ratio of 1.05. Quest Diagnostics Inc has a 12-month low of $90.10 and a 12-month high of $116.49. The stock has a market capitalization of $14.94 billion, a P/E ratio of 20.11, a price-to-earnings-growth ratio of 2.08 and a beta of 0.75.

Quest Diagnostics (NYSE:DGX) last released its quarterly earnings results on Tuesday, July 24th. The medical research company reported $1.75 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.76 by ($0.01). Quest Diagnostics had a net margin of 10.56% and a return on equity of 15.45%. The business had revenue of $1.92 billion during the quarter, compared to the consensus estimate of $1.95 billion. During the same period in the prior year, the firm earned $1.55 earnings per share. The business’s quarterly revenue was up 3.0% compared to the same quarter last year. sell-side analysts predict that Quest Diagnostics Inc will post 6.58 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, October 22nd. Investors of record on Friday, October 5th will be issued a $0.50 dividend. The ex-dividend date of this dividend is Thursday, October 4th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.85%. Quest Diagnostics’s dividend payout ratio is 37.04%.

Quest Diagnostics Profile

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services.

Recommended Story: Moving Average – How it Helps Investors in Stock Selection

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Inc (NYSE:DGX).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.